Omeros Corp. | MedPath

Omeros Advances Zaltenibart Phase 3 Trials for PNH with Potential Superiority Over Current Treatments

2 months ago

• Omeros Corporation has initiated site activation for its Phase 3 clinical trials of zaltenibart (OMS906) in paroxysmal nocturnal hemoglobinuria (PNH), with data for regulatory submission expected in Q4 2026. • Zaltenibart offers a significant advantage over current PNH therapies with convenient once-every-eight-weeks dosing and ability to inhibit both intravascular and extravascular hemolysis, potentially achieving normal hemoglobin levels. • The Phase 3 program includes head-to-head comparisons against C5 inhibitors eculizumab and ravulizumab across 120 clinical sites in 30 countries, targeting a global PNH market projected to reach $11.7 billion by 2034.